Gynecologic Cancers

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

A Randomized Controlled Trial of Robotic versus Open Surgery for Cervical Cancer (ROCC trial)

REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCI Cervical Cancer Last Mile Initiative Self-collection for HPV testing to Improve Cervical Cancer Prevention (SHIP) Trial

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRa-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCk)

Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) in HER2 Positive, Stage I-IV Endometrial Cancer

A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER

A Phase III Trial of One vs Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer